Ontology highlight
ABSTRACT: Background
Even clearly resectable pancreatic cancer still has an unfavorable prognosis. Neoadjuvant or perioperative therapies might improve the prognosis of these patients. Thus, evaluation of perioperative chemotherapy in resectable pancreatic cancer in a prospective, randomized trial is warranted. A substantial improvement in overall survival of patients with metastatic pancreatic cancer with FOLFIRINOX and nab-paclitaxel/gemcitabine vs standard gemcitabine has been demonstrated in phase III-trials. Indeed nab-paclitaxel/gemcitabine has a more favorable toxicity profile compared to the FOLFIRINOX protocol and appears applicable in a perioperative setting.Methods
NEONAX is an interventional, prospective, randomized, controlled, open label, two sided phase II study with a
SUBMITTER: Ettrich TJ
PROVIDER: S-EPMC6311014 | biostudies-literature | 2018 Dec
REPOSITORIES: biostudies-literature